Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics r&d expenses
Research and development expenses are spending on new products and technology.
Insight Molecular Diagnostics's R&D Expenses for the twelve months ending Jun 30, 2026 was $19.15M, up 69.9% year over year. For fiscal 2025 it was $15.90M, up 61.6% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $15.90M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.90M | +61.6% |
| FY2024 | Dec 31, 2024 | $9.84M | +5.9% |
| FY2023 | Dec 31, 2023 | $9.29M | +27.3% |
| FY2022 | Dec 31, 2022 | $7.30M | +45.0% |
| FY2021 | Dec 31, 2021 | $5.04M | -48.6% |
| FY2020 | Dec 31, 2020 | $9.80M | +44.2% |
| FY2019 | Dec 31, 2019 | $6.79M | +4.3% |
| FY2018 | Dec 31, 2018 | $6.51M | -9.2% |
| FY2017 | Dec 31, 2017 | $7.17M | +26.4% |
| FY2016 | Dec 31, 2016 | $5.68M | +25.4% |
| FY2015 | Dec 31, 2015 | $4.53M | +14.3% |
| FY2014 | Dec 31, 2014 | $3.96M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.49M | +37.2% |
| Q1 FY2026 | Mar 31, 2026 | $4.95M | +69.4% |
| Q4 FY2025 | Dec 31, 2025 | $5.83M | +158.3% |
| Q3 FY2025 | Sep 30, 2025 | $3.88M | +37.7% |
| Q2 FY2025 | Jun 30, 2025 | $3.27M | +33.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.92M | +26.5% |
| Q4 FY2024 | Dec 31, 2024 | $2.26M | -11.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.82M | +28.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.45M | +0.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.31M | +8.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.55M | +84.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.19M | +48.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.44M | -0.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.13M | +6.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.38M | -70.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.47M | -53.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.44M | -3.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.01M | -40.3% |
| Q4 FY2021 | Dec 31, 2021 | $4.59M | +155.1% |
| Q3 FY2021 | Sep 30, 2021 | $3.14M | +20.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.54M | -21.3% |
| Q1 FY2021 | Mar 31, 2021 | $3.36M | +55.7% |
| Q4 FY2020 | Dec 31, 2020 | $1.80M | -22.3% |
| Q3 FY2020 | Sep 30, 2020 | $2.62M | +60.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.23M | +113.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.16M | +60.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.32M | +92.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.63M | +6.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.51M | -35.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.34M | -8.1% |
| Q4 FY2018 | Dec 31, 2018 | $1.20M | -20.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.53M | -16.8% |
| Q2 FY2018 | Jun 30, 2018 | $2.32M | +16.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.46M | -20.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.51M | +5.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.84M | +34.7% |
| Q2 FY2017 | Jun 30, 2017 | $2.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.83M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.43M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.36M | – |
See a number that looks wrong?